The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a phase I study of alpelisib and sacituzumab govitecan (SG) in patients with HER2-negative metastatic breast cancer (MBC).
 
Priyanka Sharma
Stock and Other Ownership Interests - Amgen; Gilead Sciences (I); Johnson & Johnson/Janssen; Pfizer (I); Roche/Genentech (I); Sanofi
Consulting or Advisory Role - AstraZeneca; Boston Scientific (I); Cipla (I); Gilead Sciences; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer; Salient Pharmaceuticals (I); Sanofi; Stemline Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Jaimie Heldstab
Speakers' Bureau - Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
Rachel Yoder
No Relationships to Disclose
 
Joshua Staley
No Relationships to Disclose
 
India Fernandez
No Relationships to Disclose
 
Adam Heinrich
No Relationships to Disclose
 
Chasity Cupp
No Relationships to Disclose
 
Hope Owens
No Relationships to Disclose
 
Brent Sear
Employment - VisionSource (I)
Leadership - VisionSource (I)
 
Spencer Beaman
No Relationships to Disclose
 
Scott Weir
Stock and Other Ownership Interests - Lilly; Vertex
Consulting or Advisory Role - Azurity Pharmaceuticals
Research Funding - CicloMed (Inst)
Patents, Royalties, Other Intellectual Property - Co-Inventor on issued Ciclopirox Prodrug composition-of-matter and methods-of-use patents
(OPTIONAL) Uncompensated Relationships - CicloMed
 
Anne O'Dea
Honoraria - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Pfizer; Puma Biotechnology; Stemline Therapeutics
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer; Puma Biotechnology; Seagen; Stemline Therapeutics
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Pfizer; Puma Biotechnology; Stemline Therapeutics
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Pfizer; Puma Biotechnology; Stemline Therapeutics
 
Andrew Godwin
Employment - University of Kansas Health System
Stock and Other Ownership Interests - Exokeryx
Honoraria - Sinochips Diagnostics
Research Funding - Predicine (Inst); VITRAC Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Provisional - US Patent number 63/391,657 entitled “Extracellular Vesicle Proteomic Biomarker Panel for Ovarian Cancer Screening and the Early Detection of Disease”. (Inst); Provisional - US Patent number 63/496,270 entitled “Treatment of Neoplasm by Inhibiting KIF15”. (Inst); Provisional Patent application entitled - "WJMSC-Derived Small Extracellular Vesicle (sEVs) Enhance T Cell Suppression Through Checkpoint PD-L1" - Dr. Joseph McGuirk (applicant) (Inst)
 
Shane Stecklein
Honoraria - Almac Diagnostics
Consulting or Advisory Role - McKinsey & Company
Research Funding - Natera
 
Qamar Khan
No Relationships to Disclose